Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albrecht Gröner

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Transfusion|June 6, 2009
Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companiesHerbert O Dichtelmüller, Lothar Biesert, Fabrizio Fabbrizzi, et al.
Transfusion|January 22, 2011
Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companiesHerbert O Dichtelmüller, Lothar Biesert, Fabrizio Fabbrizzi, et al.
Transfusion|December 21, 2012
Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companiesKang Cai, Albrecht Gröner, Herbert O Dichtelmüller, et al.
Transfusion|August 21, 2020
Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturersNathan J Roth, Herbert O Dichtelmüller, Fabrizio Fabbrizzi, et al.
Acta Neuropathologica Communications|November 21, 2013
Rapidly progressive dementia with thalamic degeneration and peculiar cortical prion protein immunoreactivity, but absence of proteinase K resistant PrP: a new disease entity?Gabor G Kovacs, Alexander Peden, Serge Weis, et al.
The Journal of Allergy and Clinical Immunology|September 10, 2004
Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyondAngelo Agostoni, Emel Aygören-Pürsün, Karen E Binkley, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Transfusion|June 6, 2009
Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companiesHerbert O Dichtelmüller, Lothar Biesert, Fabrizio Fabbrizzi, et al.
Transfusion|January 22, 2011
Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companiesHerbert O Dichtelmüller, Lothar Biesert, Fabrizio Fabbrizzi, et al.
Transfusion|December 21, 2012
Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companiesKang Cai, Albrecht Gröner, Herbert O Dichtelmüller, et al.
Transfusion|August 21, 2020
Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturersNathan J Roth, Herbert O Dichtelmüller, Fabrizio Fabbrizzi, et al.
Acta Neuropathologica Communications|November 21, 2013
Rapidly progressive dementia with thalamic degeneration and peculiar cortical prion protein immunoreactivity, but absence of proteinase K resistant PrP: a new disease entity?Gabor G Kovacs, Alexander Peden, Serge Weis, et al.
The Journal of Allergy and Clinical Immunology|September 10, 2004
Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyondAngelo Agostoni, Emel Aygören-Pürsün, Karen E Binkley, et al.
Pageof 3